New immunosuppressants with potential implication in multiple sclerosis
about
The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptorsIsogarcinol is a new immunosuppressantDeveloping therapeutics for the treatment of multiple sclerosisFTY720 suppresses interleukin-1beta-induced secretory phospholipase A2 expression in renal mesangial cells by a transcriptional mechanism.Monocyte chemotactic protein-1 regulates voltage-gated K+ channels and macrophage transmigration.Incurred sample reanalysis of fingolimod and fingolimod phosphate in blood: stability evaluation and application to a rat pharmacokinetic study.
P2860
New immunosuppressants with potential implication in multiple sclerosis
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
New immunosuppressants with potential implication in multiple sclerosis
@ast
New immunosuppressants with potential implication in multiple sclerosis
@en
New immunosuppressants with potential implication in multiple sclerosis
@nl
type
label
New immunosuppressants with potential implication in multiple sclerosis
@ast
New immunosuppressants with potential implication in multiple sclerosis
@en
New immunosuppressants with potential implication in multiple sclerosis
@nl
prefLabel
New immunosuppressants with potential implication in multiple sclerosis
@ast
New immunosuppressants with potential implication in multiple sclerosis
@en
New immunosuppressants with potential implication in multiple sclerosis
@nl
P1476
New immunosuppressants with potential implication in multiple sclerosis
@en
P2093
R E Gonsette
P356
10.1016/J.JNS.2004.04.025
P407
P577
2004-08-15T00:00:00Z